Canagliflozin hemihydrate |
カタログ番号GC35603 |
カナグリフロジン半水和物 (JNJ28431754 半水和物) は選択的 SGLT2 阻害剤であり、CHOK 細胞の mSGLT2、rSGLT2、および hSGLT2 に対してそれぞれ 2 nM、3.7 nM、および 4.4 nM の IC50 を示します 。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 928672-86-0
Sample solution is provided at 25 µL, 10mM.
Canagliflozin hemihydrate (JNJ28431754 hemihydrate; TA-7284 hemihydrate) is a selective SGLT2 inhibitor with IC50s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively[1]. IC50: 2/3.7/4.4 nM (mSGLT2/rSGLT2/hSGLT2, in CHOK cells)[1]
Canagliflozin inhibits Na+-dependent 14C-AMG uptake in CHO-hSGLT2 cells, with an IC50 of 4.4±1.2 nM. Similar IC50 values are obtained in CHO-rSGLT2 and CHO-mSGLT2 cells (IC50 = 3.7 and 2.0 nM for rat and mouse SGLT2, respectively). Canagliflozin inhibits 14C-AMG uptake in CHO-hSGLT1 and mSGLT1 cells with IC50 of 684±159 nM and >1,000 nM, respectively[1].
Canagliflozin (30 mg/kg treatment for 4 weeks) reduced blood glucose (BG) levels, respiratory exchange ratio, and body weight gain in DIO mice[1].Canagliflozin (3 mg/kg for 3 weeks) increases urinary glucose excretion (UGE) with no significant change in total food intake compared with that in vehicle-treated rats, leading to a decrease in body weight In ZF rats[1]. Animal Model: Diet-induced obese, insulin resistantmice (DIO) Mice[1]
[1]. Liang Y, et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models.PLoS One. 2012;7(2):e30555.
Average Rating: 5
(Based on Reviews and 3 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *